SCHEMBL3548458

SCHEMBL3548458

Oc1ccc(Br)cc1SC(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 5/20 0.45
HPGD P15428 3/20 0.39
CASP1 P29466 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
CES2 O00748 1/20 0.39
GALR3 O60755 1/20 0.39
CYP1A2 P05177 1/20 0.39
ERN1 O75460 2/20 0.38
TMPRSS4 Q9NRS4 1/20 0.36
KCNK2 O95069 2/20 0.36
KCNK10 P57789 2/20 0.36
GSTA1 P08263 1/20 0.34
BCL2 P10415 1/20 0.33
MCL1 Q07820 1/20 0.33
WDR5 P61964 1/20 0.33
ALOX12 P18054 2/20 0.33
IDO1 P14902 1/20 0.33
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27177082 0.78 POLB (0.42) KCNK2KCNK10ALDH1A1
SCHEMBL31620868 0.78 POLB (0.42) KCNK2KCNK10ALDH1A1
SCHEMBL11316818 0.76 ALOX15 (0.54) ALOX15HPGDCASP1CYP2C9CYP2C19
SCHEMBL18247943 0.73 PDE2A (0.44) HPGDKCNK2KCNK10ALOX12LMNA
SCHEMBL27987978 0.72 ALOX15 (0.50) ALOX15HPGDCASP1CYP2C9CYP2C19
SCHEMBL28099073 0.72 ALDH1A1 (0.50) ALOX15HPGDERN1TMPRSS4KCNK2
SCHEMBL28099220 0.72 ALOX5 (0.52) ALOX15HPGDCYP1A2GSTA1MCL1
SCHEMBL14808660 0.72 SLC6A4 (0.47) KCNK2KCNK10MEN1KMT2AHSD17B10
SCHEMBL3542339 0.70 ALDH1A1 (0.41) ALOX15HPGDCA12HSD17B10LMNA
SCHEMBL29788344 0.70 ALDH1A1 (0.41) ALOX15HPGDCA12HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE ALOX15 4471/4885HPGD 688/4885CASP1 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.